Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
about
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.SHP family protein tyrosine phosphatases adopt canonical active-site conformations in the apo and phosphate-bound statesDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma.Programmed cell death receptor ligand 1 modulates the regulatory T cells' capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1.SHP-1 phosphatase activity counteracts increased T cell receptor affinity.Recent discoveries in the cycling, growing and aging of the p53 fieldCommon drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant miceMolecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.Role of SHP2 in hematopoiesis and leukemogenesis.Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
P2860
Q26744624-7D1D9F69-0DA2-4B78-A44E-4FA8DAF0D068Q27684212-E5623CF0-DEFD-4CB1-AB72-97233FD7DADAQ34103963-4666C00C-148A-4584-B08F-9F2DC02DDB7DQ34285853-3B8EDAC9-D209-492C-97E3-8DDE49E067E3Q34725579-BAF4E1BE-D95C-4FA3-BD7F-678D4199DDAAQ36638160-24A1A77D-424F-4CFA-8E0C-37F91F2FD276Q36736358-DD70A52B-5367-441A-A0E8-6B67BFEC5802Q36926148-3FE4ADF9-460D-4E5F-B586-E229AA7C41A0Q36962480-6D8B2AD3-25E3-4B38-9CF7-39A55971965BQ39065291-1DD4AB47-56FE-4806-BC4A-4144B181CF16Q39088131-7E910D89-5752-40DA-9F8D-CDFC8C41F22DQ39184182-B5FD5258-E392-4DE4-B1E4-BAC506575B1AQ42234959-3FD82F9D-50D8-4BA0-A6ED-839CFBF9DDE9
P2860
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@ast
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@en
type
label
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@ast
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@en
prefLabel
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@ast
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@en
P2093
P2860
P356
P1433
P1476
Phosphatase inhibitor, sodium ...... odynamic and clinical effects.
@en
P2093
Barbara Jacobs
Emese Hollovary
Ernest C Borden
Masato Mitsuhashi
Paul Elson
Pierre Triozzi
Thomas G Budd
Timothy Spiro
P2860
P304
P356
10.18632/ONCOTARGET.393
P407
P577
2011-12-01T00:00:00Z